Australia's Pro Medicus rises to 1-month high as Citi upgrades PT, rating
Shares of Pro Medicus PME.AX rise as much as 7.6% to A$321.57, their highest level since August 18
Stock among the top gainers in the S&P/ASX 200 index .AXJO, which is up 0.5%; healthcare stocks .AXHJ climb 2%
Citi upgrades stock rating to "buy" from "sell", and PT to A$350 from A$220
Brokerage expects the recent licensing agreement to commercialize breast cancer detection algorithm it co-created to act as a revenue lever and deepen its moat
Brokerage raised revenue growth forecasts from 20% in five years' time to mid-high 20s% given the higher renewal rates for PME's long contracts, among others
Stock currently up 5%, bringing YTD gains to 25.4%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey





